Trial Profile
A Randomised PhIII study to assess the effect of 100 mg SC Mepolizumab in the nasal polyp score and symptoms in subjects with bilateral Nasal polyps (NP) and in current need of NP surgery
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Nasal polyps
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 Jul 2016 New trial record